Leronlimab for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial provides access to an investigational drug called leronlimab for people with advanced triple-negative breast cancer who have exhausted standard options. Leronlimab is given as an injection and may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (stage IIIB or IV) triple-negative breast cancer that has grown after standard treatments, or you cannot take standard treatments.
- You are able to attend follow-up visits and follow the study requirements.
- Your daily activity level is good (ECOG score 0 to 2).
- If you have had brain metastases, they must be stable for at least 4 weeks and without symptoms.
- You are willing to provide a new tumor biopsy if no archived tissue is available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Hear when a new TNBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.